期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙芬酰胺的合成 被引量：7

Synthesis of Safinamide
原文传递
导出
摘要 3-氟氯苄与对羟基苯甲醛反应制得4-(3-氟苄氧基)苯甲醛,而后与(S)-2-氨基丙酰胺缩合、Pd/C催化氢化还原,最后与甲磺酸成盐制得抗帕金森病药沙芬酰胺,总收率约76%。 Safinamide, an antiparkinson drug, was synthesized from 3-fluorobenzyl clalonae oy suosnmuon witu 4-hydroxybenzaldehyde to give 4-（3-fluorobenzyloxy） benzaldehyde, which was subjected to condensation and reduction to give （S）-2-[4-（3-fluorobenzyloxy）benzylamino）propionamide, followed by salification with methanesulfonic acid, The overall yield was about 76 %.
作者 邢瑞娟 律涛 刘磊娜 朱梦楚 杜玉民
机构地区 河北医科大学药学院药物化学教研室 江苏大学基础医学与医学技术学院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2012年第3期161-163,共3页 Chinese Journal of Pharmaceuticals
关键词 沙芬酰胺 抗帕金森病药 合成 safinamide antiparkinsonism drug synthesis
分类号 R971.5 [医药卫生—药品]
  • 相关文献

参考文献10

  • 1Schapira AH.Safinamide in the treatment of Parkinson'sdisease[J].Expert Opin Pharmacother,2010,11(13):2261-2268.
  • 2Onofrj M,Bonanni L,Thomas A.An expert opinion onsafinamide in Parkinson’s disease[J].Expert Opin InvestigDrugs,2008,17(7):1115-1125.
  • 3Stocchi F,Arnold G,Onofrj M,et al.Improvement of motorfunction in early Parkinson disease by safinamide[J].Neurology,2004,63(4):746-748.
  • 4Stocchi F,Vacca L,Grassini P,et al.Symptom relief inParkinson disease by safinamide:biochemical and clinicalevidence of efficacy beyond MAO-B inhibition[J].Neurolo-gy,2006,67(7 suppl 2):S24-29.
  • 5Francesco L,Carmelida C,Leonardo P,et al.Solid-phasesynthesis and insights into structure activity relationships ofsafinamide analogues as potent and selective inhibitors oftype B monoamine oxidase[J].J Med Chem,2007,50(20):4909-4916.
  • 6Pevarello P,Bonsignori A,Dostert P,et al.Synthesis andanticonvulsant activity of a new class of 2-[(arylalky)-amino]alkanamide derivatives[J].J Med Chem,1998,41(4):579-590.
  • 7张成根,李文佐,黄明宝.溶液中甲醇和二氯亚砜的化学反应[J].物理化学学报,2007,23(3):399-403. 被引量：7
  • 8Nicola F,Ga lle FA,Bálint K,et al.Synthesis of awater-soluble chiral NMR shift reagent:(S)-PDTA[J].Tetrahedron:Asymmetry,2009,20(9):1036-1039.
  • 9Salom C,Salom E,Stables JP,et al.Merging the structuralmotifs of functionalized amino acids and alpha-aminoamides:compounds with significant anticonvulsant activities[J].JMed Chem,2010,53(9):3756-3771.
  • 10刘磊娜,律涛,赵晓娟,李飞高,杜玉民.沙芬酰胺中R-型对映体的HPLC法测定[J].中国医药工业杂志,2010,41(12):934-936. 被引量：1

二级参考文献32

  • 1佚名.Safinamide可改善早期帕金森病症状.药学进展,2007,31(10):476-476.
  • 2Fariello RG.Safinamide[J].Neurotherapeutics,2007,4(1):110-116.
  • 3Leonetti F,Capaldi C,Pisani L,et al.Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase[J].J Med Chem,2007,50(20):4909-4916.
  • 4Pevarello P,Bonsignori A,Dostert P,et al.Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl)ami no] alkanamide derivatives[J].J Med Chem,1998,41(4):579-590.
  • 5Barbanti E,Veneroni O,Thaler F,et al.Alpha-aminoamide derivative useful in the treatment of lower urinary tract disorders:WO,2005070405[P].2005-08-04.
  • 6Piero M,Alessandra R,Simona F,et al.Substituted 2-[2-(phenyl)ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators:WO,2008151702[P].2008-12-18.
  • 7Liu JL.Alpha-aminoamide derivatives:WO,2009054964[P].2009-04-30.
  • 8Lewis,E.S.; Boozer,C.E.J.Am.Chem.Soc.,1952,74:308
  • 9Lewis,E.S.; Boozer,C.E.J.Am.Chem.Soc.,1953,75:3182
  • 10Lewis,E.S.; Coppinger,G.M.J.Am.Chem.Soc.,1954,76:796

共引文献6

同被引文献49

  • 1STOCCHI F,BORGOHAIN R,ONOFR J M,et al.A rando- mized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients[ J ]. Mov Disord ,2012,27( 1 ) : 106-112.
  • 2SCHAPIRA A H,STOCCHI F,BORGOHAIN R,et al.Long- term efficacy and safety of snamide as add-on therapy in early Parkinson's disease [ J ]. Ear J' Neurol, 2013,20 ( 2 ) : 271-280.
  • 3LEWITT P A, HAUSER R A, LU M, et al. Randomized cli- nical trial of fipamezole for dyskinesia in Parkinson disease ( FJORD study) [ J] .Neurology ,2012,79(2) :163-169.
  • 4MIZUNO Y, KONDO T.Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease [ J] .Mov Disord,2013,28(8) : 1138-1141.
  • 5MARIE A B,KEVIN R W N,TERESA T Z,et al.c-Jun N- terminal kinase (JNK) signaling: recent advances and challenges [ J 1- Biochim Biophys Acta, 2010, 1804 ( 3 ) : 463- 475.
  • 6CHAMBERS J W, PACHORI A, HOWARD S, et al. Smallmolecule e-jun-N-Terminal kinase inhibitors protect dopaminergic neurons in a model of Parkinson "s disease [ J ]. ACS Chem Neurosci, 2011,2 (4) : 198- 206.
  • 7KRAMER T, MONTE F L, GORING S,et al.Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models [ J ]. ACS Chem Neurosci, 2012, 3(3) :151-160.
  • 8MCFARLAND K,PRICE D L, DAVIS C N, et aI.AC-186, a selective nonsteroidal estrogen receptor 13 agonist, shows gender specific neuroprotection in a Parkinson's disease rat model[J].ACS Chem Neurosci,2013,4(9):1249-1255.
  • 9MURATA M, HORIUCHI E,KANAZAWA I.Zonisamide has beneficial effects on Parkinson "s disease patients [ J ]. Neurosci Res, 2001,41 (4) : 397-399.
  • 10STOCCHI F.Therapy for Parkinson's disease: what is in thepipeline.'? [ J ]. Neurotherapeutics, 2014,11 ( 1 ) : 24-33.

引证文献7

二级引证文献13

中国医药工业杂志
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部